The endothelial glycocalyx integrates mechanical signals with vascular biology, playing a vital role in health and disease, ...

In a study being published in the March issue of Phytomedicine and published online ahead of print, CBD was found to protect ...

Europe and the biobased chemical industry—are enjoying a bit of good news, as our weekly roundup below shows. In Europe, the ...

Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this ...

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

In recent years, interest has grown around two investigational peptides, BPC-157 and TB-500, proposed as part of a combined research-oriented protocol to explore tissue regeneration, angiogenesis, and ...

Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...

A recent Financial Times report stated that Merck MRK is in talks to buy Redwood City, CA-based cancer biotech, Revolution Medicines RVMD, in a transaction that could value RVMD for up to $32 billion.

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...